We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Eastern Europe,Australasia,Asia,Middle East,Africa
Sample Provided: no
Jiangsu Xinhe Biomedicine Co., LTD. (Jiangsu Xinhe). The company is a comprehensive enterprise integrating research and development, production and sales of pharmaceutical intermediates, fine chemicals and customized synthesis. Mainly good at industrial enzyme preparation research and development; Sales of new catalytic materials and additives; Engineering and technology research and experimental development; Biotechnology product technology research and development; In particular, it is devoted to the technology of asymmetric chiral catalysis, providing new ideas and research directions for pharmaceutical intermediates and special chemistry. Company R & D and sales center is located in Nanjing Life Science and technology town, with HPLC, GC and other complete testing equipment.
At present, it has Tianchang Base in Anhui Province, Xinyang base in Henan Province and Guangde base in Anhui Province, which provides a strong guarantee for the product's small trial, pilot trial to large-scale production.
Audited Supplier
Pharma Sources Insight June 2024: Globalization on the Go
![6-Aminomethyl-6,11-dihydro-
5H-dibenz[b,e]azepine (E)-2-butenedioate](https://eimg.pharmasources.com/img_Cphi_en/Product/2018_08/Mimg_1808160218395251.jpg!145)
![RUCL(P-CYMENE)((R)-DTBM-SEGPHOS)]CL](https://eimg.pharmasources.com/image/product/20240115/7ed368ff56b8de3a486c66e9b429a353jpg!145)
